<DOC>
	<DOCNO>NCT00385853</DOCNO>
	<brief_summary>PTK investigational new drug show early laboratory study prevent formation new blood vessel allow tumor grow . These study show study drug potentially improve effectiveness additional radiation chemotherapy . With study , would like examine effect PTK use combination radiation therapy anti-cancer drug temozolomide , standard treatment patient newly diagnose glioblastoma . We would also like learn study drug absorb , distribute , clear body .</brief_summary>
	<brief_title>PTK787/ZK 222584 Combination With Temozolomide Radiation Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs</brief_title>
	<detailed_description>- Since look high dose PTK administer safely without severe unmanageable side effect , everyone participates get dose PTK . A small group enrol onto study give certain dose . If tolerate well , next small group enrol receive high dose . This continue high dose give without severe unmanageable side effect find . - Participants receive PTK twice daily along temozolomide daily treatment cycle . Each treatment cycle last 28 day . - PTK start Day 0 first cycle give twice daily 7 week participant receives radiation therapy . - Daily dos temozolomide begin Day first cycle continue last dose radiation therapy cycle 1 . - Each participant receive 7 week radiation therapy . Radiation therapy start Day 5 first cycle administer monday friday , except holiday . - When radiation stop , temozolomide PTK give maximum 6 post-radiation cycle study treatment . During cycle , PTK temozolomide give 5 consecutive day follow 23 day drug . - Tests perform routinely throughout study treatment include ; chest x-ray , blood test , physical exam , urine test ECG . - The following procedure perform end study participant last dose study medication ; tumor assessment MRI , routine blood draw , neurological/physical exam , medical history review .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>All patient must histologically verified glioblastoma . Patients mus paraffin block tumor must send analysis . 18 year age old Karnofsky Performance Status great equal 60 Adequate laboratory value describe protocol Life expectancy great 12 week Patient must able undergo serial MR imaging Patients must enzymeinducing antiepileptic drug ( ) list protocol No steroid stable dose steroid least 5 day decrease dose Minimental status examination 15 great Pregnant breastfeed woman Concurrent malignancy except curatively treat basal squamous cell carcinoma skin carcinoma situ cervix breast Prior chemotherapy cranial radiation therapy glioblastoma Prior biologic immunotherapy le 2 week prior registration If patient surgery 16 day less 13 day start PTK787/ZK 222854 Prior therapy antiVEGF agent Pleural effusion ascites cause respiratory compromise Concurrent severe and/or uncontrolled medical condition could compromise participation study Impairment gastrointestinal function GI disease may significantly alter absorption PTK787/ZK 222584 Confirmed diagnosis human immunodeficiency virus ( IV ) Patients take therapeutic warfarin sodium anticoagulant antiplatelet agent Patients require aprepitant , dolasetron , tropisetron antiemetic exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>PTK</keyword>
	<keyword>temozolomide</keyword>
	<keyword>glioblastoma</keyword>
</DOC>